Pfizer, Novartis and Janssen, the pharmaceutical companies with the best reputation in Spain in the year of the pandemic
02/06/2021

This Wednesday, June 2, the ranking of the pharmaceutical companies with the best reputation in Spain in 2020 was presented at an online event. The pandemic has increased the social and media relevance of the health sector as a whole, including pharmaceutical companies, some of them manufacturers of the vaccines that protect against COVID-19. After conducting 6,733 surveys of health professionals at all levels and areas, managers, journalists specialized in health or representatives of public administrations, the Health Reputation Monitor places on the podium of its ranking of pharmaceutical companies with the best reputation in Spain Pfizer, Novartis and Janssen. The top 10 of the most reputable pharmaceutical companies are completed by Astrazeneca, Sanofi, GSK, Roche, Bayer, Lilly and MSD.
Regarding the pharmaceutical companies with the best reputation by therapeutic area, Pfizer leads the ranking in nine, Janssen in four areas, GSK in three, Novartis in two; Amgen, Astellas Pharma, Bayer, Novo Nordisk and Roche do it in one.
In turn, Pfizer, Novartis, Janssen, GSK and Astrazeneca lead the ranking of the most innovative pharmaceutical companies.
The ranking of healthcare technology companies is led by Siemens, General Electric and Philips; while the most reputable manufacturers of biomedical devices are Depuy Synthes, Kls Martin and Stryker.
Finally, the pharmaceutical companies with the best communication management for health informants (ANIS) are Novartis, Roche and Pfizer.
In this 7th edition, 12 evaluations and 6,733 surveys have been carried out with professionals-stakeholders in the health field: Doctors from 26 specialties, directors of pharmaceutical companies, nurses, managers and directors of hospitals, members of the public health administration and heads of pharmacy areas health, nurse managers, hospital pharmacists, patient associations and health informants; in addition to the evaluation of 200 objective indicators of pharmaceutical companies.
This year, as a novelty, the analysis of the digital reputation of pharmaceutical companies has been included through more than 760,000 mentions in digital media, influencers and users.
The Health Reputation Monitor (MRS) is the only independent study that analyzes the reputation of all Spanish healthcare. To achieve this, a verification process with three phases has been carried out: the first, the assessment carried out by medical professionals from 26 specialties -started in November 2020-; the second the assessment of managers and heads of hospitals, nurses, nurse managers, directors of pharmaceutical companies, hospital pharmacy managers, patient associations, journalists and health informants, as well as members of the public health administration - which started in March from 2021-; In addition, these evaluations are complemented by a third analysis: an objective evaluation of reputational merits carried out by the Merco technicians, who are responsible for MRS field work.
The production process has been subjected to an independent review by KPMG in accordance with the ISAE 3000 standard, and has the endorsement of collegiate organizations of doctors and nurses, as well as patient associations and health journalists.
Related documents
Nota de prensa MRS Empresas Farmacéuticas (7ªedicion) (PDF, 208Kb)